Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Stock Information for Evogene Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evogene Ltd.

Evogene Reports Third Quarter 2025 Financial Results
Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming
Evogene Schedules Third Quarter 2025 Financial Results Release
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene Reports Second Quarter 2025 Financial Results
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.